JW Group announced on the 1st that it has signed a joint research contract with U.S. bio venture company KURE AI Therapeutics to develop innovative anti-cancer drugs based on artificial intelligence (AI). Under this contract, JW Pharma and JW CreaGene will launch research and development of three new anticancer drugs using KURE AI's artificial intelligence and machine learning-based genetic analysis and biomarker search platform.

JW Pharmaceutical will discover a new low-molecular anticancer drug task with KURE AI targeting patients with immune anticancer drug-resistant solid cancer. It will also establish a strategy to increase the clinical success rate of candidates for new anticancer drugs developed